AI Summary & Key Takeaways
AI InsightWe found that the Caspase 3 level is not a reliable biomarker in patients whose stroke onset is unknown.
📌 3 Key Takeaways
Abstract
Background and Purpose: This study aims to investigate the relationship between the stroke duration and Caspase 3 levels, measured in patients presenting to the emergency department in whom the time of stroke onset is known, and to seek an answer to the question of whether thrombolytics can be applied through the Caspase 3 levels in patients whose onset time of stroke is unknown. Methods: A total of 100 patients with ischemic stroke who applied to the emergency department in a six-month period and 50 healthy control groups were included in the study. Age, gender, comorbid diseases, stroke onset times, and ischemic brain tissue volume of the patients who underwent brain diffusion magnetic resonance (MR) were calculated and recorded. Caspase 3 levels were studied from the blood taken from the patient and control groups. Results: The mean age of the patients was 68.57±13.25. 45% were male When Caspase 3 levels were considered in neurological examination findings, only the median of those without facial paralysis was higher (p=0.033). No significant and linear correlation was found between the Caspase 3 levels with the ischemic volume and National Institutes of Health Stroke Scale (NIHSS) scores of stroke patients (p=0.831 and p=0.949). Additionally, no significant correlation was found between stroke duration and Caspase 3 levels (p=0.733). Conclusion: No significant relationship was found between the ischemic stroke patients and the control group in terms of Caspase 3 levels. We found that the Caspase 3 level is not a reliable biomarker in patients whose stroke onset is unknown.